Balyasny Asset Management LLC Larimar Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 79,496 shares of LRMR stock, worth $264,721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,496Holding current value
$264,721% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$70.7 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$21.5 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20.1 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$15.5 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.8 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $144M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...